Iterum Therapeutics Announces Expiration and Preliminary Results of Rights Offering
31 août 2020 20h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Commences Rights Offering
11 août 2020 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2020 Financial Results
06 août 2020 06h45 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Offering
13 juil. 2020 16h05 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
30 juin 2020 09h12 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics...
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
29 juin 2020 07h30 HE
|
Iterum Therapeutics plc
Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to discuss NDA filing with FDA DUBLIN, Ireland and CHICAGO, June 29, 2020 (GLOBE NEWSWIRE)...
Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting
15 juin 2020 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 15, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
03 juin 2020 09h50 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
01 juin 2020 08h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports First Quarter 2020 Financial Results
14 mai 2020 06h45 HE
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...